

Infliximab Quantitation with Antibodies to Infliximab,
Serum

Patient ID SA00164754	Patient Name TESTINGRNV, INFXP AB	Birth Date 1980-09-09	Sex M	Age 43
Order Number SA00164754	Client Order Number SA00164754	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 20 Nov 2023 00:00		

Infliximab QN with Antibodies, S

Infliximab, S

Interpretation

See the INXAB Interpretation for the final infliximab panel interpretation.

1 SDL

Infliximab, S

SDL



5.0 mcg/mL

Low

REFERENCE VALUE

Limit of Quantitation = 1.0 mcg/mL

Infliximab Ab, S

INXAB Interpretation

Presence of antibody-to-infliximab (ATI) detected. At this concentration of infliximab (IFX), the detected titer of the ATI may be modestly underestimated.

This test has demonstrated drug tolerance of up to 100 mcg/mL IFX for ATI ≥500 U/mL and up to 10 mcg/mL IFX for ATI < 500 U/mL.

1 SDL

Infliximab Ab, S

SDL



55.2 U/mL

High

Reference Value
<50.0

Received: 21 Nov 2023 09:40

Reported: 21 Nov 2023 09:45

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	William G. Morice M.D. Ph.D.	24D1040592